US Patent

US10292990 — Abiraterone steroid formulation

Method of Use · Assigned to Sun Pharma Global FZE · Expires 2034-05-20 · 8y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treating prostate cancer by administering a nanoparticulate composition of abiraterone acetate together with a glucocorticoid.

USPTO Abstract

A nanoparticulate composition of abiraterone acetate that allows treatment at a lower dose than convention abiraterone acetate formulations is described as in a method of treating prostate cancer by administering the composition together with a glucocorticoid.

Drugs covered by this patent

chembl-chembl271227 (ABIRATERONE ACETATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2535`	—	chembl-chembl271227

Patent Metadata

Patent number: US10292990
Jurisdiction: US
Classification: Method of Use
Expires: 2034-05-20
Drug substance claim: No
Drug product claim: No
Assignee: Sun Pharma Global FZE
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.